Search
Xeris Biopharma Holdings Inc
XERSAdd to Watchlist
8.080USD
-0.340-4.04%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.39BMarket Cap
104.89P/E TTM
More Details of Xeris Biopharma Holdings Inc Company
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
Xeris Biopharma Holdings Inc Info
Ticker SymbolXERS
Company nameXeris Biopharma Holdings Inc
IPO dateJun 21, 2018
CEOShannon (John P)
Number of employees394
Security typeOrdinary Share
Fiscal year-endJun 21
Address1375 West Fulton Street, Suite 1300
CityCHICAGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code60607
Phone18444455704
Websitehttps://www.xerispharma.com/
Ticker SymbolXERS
IPO dateJun 21, 2018
CEOShannon (John P)
Company Executives of Xeris Biopharma Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin McCulloch
Mr. Kevin McCulloch
President, Chief Operating Officer
President, Chief Operating Officer
1.15M
-7.80%
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
665.21K
-2.51%
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Independent Director
Independent Director
188.34K
+12.85%
Dr. Jeffrey W. Sherman, M.D.
Dr. Jeffrey W. Sherman, M.D.
Independent Director
Independent Director
174.59K
--
Ms. Marla S. Persky, J.D.
Ms. Marla S. Persky, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
107.06K
+8.12%
Ms. Dawn Halkuff
Ms. Dawn Halkuff
Independent Director
Independent Director
74.60K
+5.62%
Mr. John P. Shannon
Mr. John P. Shannon
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. BJ Bormann, Ph.D.
Dr. BJ Bormann, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven M. Pieper
Mr. Steven M. Pieper
Chief Financial Officer
Chief Financial Officer
--
--
Mr. John H. Johnson
Mr. John H. Johnson
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin McCulloch
Mr. Kevin McCulloch
President, Chief Operating Officer
President, Chief Operating Officer
1.15M
-7.80%
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
665.21K
-2.51%
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Independent Director
Independent Director
188.34K
+12.85%
Dr. Jeffrey W. Sherman, M.D.
Dr. Jeffrey W. Sherman, M.D.
Independent Director
Independent Director
174.59K
--
Ms. Marla S. Persky, J.D.
Ms. Marla S. Persky, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
107.06K
+8.12%
Ms. Dawn Halkuff
Ms. Dawn Halkuff
Independent Director
Independent Director
74.60K
+5.62%
FAQs
Who are the top five shareholders of Xeris Biopharma Holdings Inc?
The top five shareholders of Xeris Biopharma Holdings Inc are: Mr. Kevin McCulloch
What is the biggest source of revenue for Xeris Biopharma Holdings Inc?
In 2026Q4, the Product revenue -Recorlev business generated the highest revenue for Xeris Biopharma Holdings Inc, amounting to 36.98M and accounting for 49.71% of total revenue.